Rational Pharmacotherapy in Cardiology

Advanced search


Full Text:


The possibility of atorvastatin in reducing the risk of periprocedural myocardial infarction and other cardiovascular events in patients with percutaneous coronary intervention is discussed.

About the Author

N. G. Gogolashvili
Scientific Research Institute of Medical Problems of the North, Krasnoyarsk State Medical University named after V.F. Voino-Yasenetsky
Russian Federation

Partizana Zheleznyaka ul. 3G, Krasnoyarsk, 660022 Russia

Partizana Zheleznyaka ul. 1, Krasnoyarsk, 660022 Russia


1. Levine G.N., Bates E.R., Blankenship J.C. et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundationю American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 2011;58:e44-122.

2. Alekyan BG, Abrosimov AV. The current state of endovascular treatment of acute coronary syndrome and its development prospects in the Russian Federation. Complex Problems of Cardiovascular Disease 2013; (1): 5-9. Russian (Алекян Б. Г., Абросимов А. В. Современное состояние рентгенэндоваскулярного лечения острого коронарного синдрома и перспективы его развития в Российской Федерации. Комплексные Проблемы Сердечно-сосудистых Заболеваний 2013;(1):5-9).

3. Melfi R., Nusca A., Patti G., Di Sciascio G. Statins and their role in pre-percutaneous coronary intervention. Curr Cardiol Rep 2010;12(4):295-301.

4. Nusca A., Melfi R., Patti G., Sciascio G.D. Statin loading before percutaneous coronary intervention: proposed mechanisms and applications. Future Cardiol 2010;6(5):579-89.

5. Mega S., Nusca A., Patti G. Prevention of complications after percutaneous coronary interventions with statins. Recenti Prog Med 2012;103(1):5-10.

6. Guarini G, Marzilli M. Defining the role of high-dose statins in PCI. Am J Cardiovasc Drugs 2013;13(3):189-97.

7. Blankenship J.C., Haldis T., Feit F. et al. Angiographic adverse events, creatine kinase-MB elevation, and ischemic end points complicating percutaneous coronary intervention (a REPLACE-2 substudy). Am J Cardiol 2006;97(11):1591-6.

8. Jang .S., Jin H.Y., Seo J.S. et al. Prognostic value of creatine kinase-myocardial band isoenzyme elevation following percutaneous coronary intervention: a meta-analysis. Catheter Cardiovasc Interv 2013;81(6):959-67.

9. Briguori C., Colombo A., Airoldi F. et al. Statin administration before percutaneous coronary intervention: impact on periprocedural myocardial infarction. Eur Heart J 2004;25:1822-8.

10. Winchester D.E., Wen X., Xie L., Bavry A.A. Evidence of pre-procedural statin therapy: a meta-analysis of randomized trials. J Am Coll Cardiol 2010;56:1099-109.

11. Yun K.H., Jeong M.H., Oh S.K. et al. The beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome. Int J Cardiol 2009;137:246-51.

12. Jia X.W., Fu X.H., Zhang J. et al. Intensive cholesterol lowering with statin improves the outcomes of percutaneous coronary intervention in patients with acute coronary syndrome. Chin Med J (Engl) 2009;122:659-64.

13. Bozbas H., Yildirir A., Mermer S. et al. Does pravastatin therapy affect cardiac enzyme levels after percutaneous coronary intervention? Adv Ther 2007;24:493-504.

14. Pasceri V., Patti G., Nusca A. et al. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of Myocardial Damage during Angioplasty) study. Circulation 2004;110:674-8.

15. Patti G., Pasceri V., Colonna G. et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDAACS randomized trial. J Am Coll Cardiol 2007;49:1272-8.

16. Di Sciascio G., Patti G., Pasceri V. et al. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) randomized trial. J Am Coll Cardiol 2009;54:558-65.

17. Veselka J., Zemanek D., Hajek P. et al. Effect of two-day atorvastatin pretreatment on the incidence of periprocedural myocardial infarction following elective percutaneous coronary intervention: a singlecenter, prospective, and randomized study. Am J Cardiol 2009;104:630-3.

18. Briguori C., Visconti G., Focaccio A. et al. Novel approaches for preventing or limiting events (NAPLES) II trial impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction. J Am Coll Cardiol 2009;54:2157-63.

19. Kinoshita M., Matsumura S., Sueyoshi K. et al. Randomized trial of statin administration for myocardial injury: is intensive lipid-lowering more beneficial than moderate lipid-lowering before percutaneous coronary intervention? Circ J 2007;71:1225-8.

20. Zhang F., Dong L., Ge J. Effect of statins pretreatment on periprocedural myocardial infarction in patients undergoing percutaneous coronary intervention: a meta-analysis. Ann Med 2010;42(3):171-7.

21. Patti G., Cannon C.P., Murphy S.A. et al. Clinical benefit of statin pretreatment in patients undergoing percutaneous coronary intervention: a collaborative patient-level meta-analysis of 13 randomized studies. Circulation 2011;123:1622-32.

22. Kim J.S., Kim J., Choi D. et al. Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN STEMI trial. JACC Cardiovasc Interv 2010;3:332-9.

23. Hara H., Nakamura M., Yokouchi I. et al. Aggressive statin therapy in multicenter and effectiveness for the reduction of intramyocardial damage caused by non-ST elevation acute coronary syndrome: AMERICA study. Ther Adv Cardiovasc Dis 2009;3:357-65.

24. Cay S., Cagirci G., Sen N. et al. Prevention of peri-procedural myocardial injury using a single high loading dose of rosuvastatin. Cardiovasc Drugs Ther 2010;24:41-7.

25. Zemánek D., Branny М., MartinkovičováL. et al. Effect of seven-day atorvastatin pretreatment on the incidence of periprocedural myocardial infarction following percutaneous coronary intervention in patients receiving long-term statin therapy. A randomized study. International Journal of Cardiology 2013;168 (3):2494-97.

26. Veselka J., Hajek P., Tomašov P. et al. Effect of rosuvastatin therapy on troponin I release following percutaneous coronary intervention in nonemergency patients (from the TIP 3 Study). American Journal of Cardiology 2014; 113(3): 446-51.

27. Sun Y., Qi G., Gao Y. et al. Effect of different loading doses of atorvastatin on percutaneous coronary intervention for acute coronary syndromes. Can J Cardiol 2010;26:481-5.

28. Lavie C. J., Milani R.V. High-dose atorvastatin in acute coronary and cerebrovascular syndromes. J Am Coll Cardiol 2010; 3(3): 332-42.

29. Norris D.M., Anderson J.R. Statin loading before percutaneous coronary intervention to reduce periprocedural myocardial infarction. Cardiology in Review 2012;20: 319-24.

30. Leoncini M., Toso A., Maioli M. et al. Statin treatment before percutaneous cononary intervention. J Thorac Dis 2013;5(3):335-42.

31. Semenova AE, Kuharchuk VV. Intensive therapy with atorvastatin. Improving the effectiveness of treatment. Dyslipidemia and Atherosclerosis 2011; (2): 36-42. Russian (Семенова А. Е., Кухарчук В. В. Интенсивная терапия аторвастатином. Повышение эффективности лечения. Атеросклероз и Дислипидемии 2011;(2): 36-42).

32. Oganov RG, Buziashvili YI, Kuharchuk VV et al. Council of RSSC, NSA, RSCRP, NAAS Experts. Optimizing statin treatment of patients at high and very high cardiovascular risk. Kardiosomatika 2011 (4): 80-6. Russian (Оганов Р.Г., Бузиашвили Ю.И., Кухарчук В.В. и соавт. Заключение Совета экспертов ВНОК, НОА, РосОКР, НАБИ. Оптимизация терапии статинами пациентов высокого и очень высокого сердечно-сосудистого риска. Кардиосоматика 2011;(4): 80-6).

33. Diagnosis and correction of lipid disorders for the prevention and treatment of atherosclerosis. Russian recommendations (Vth revision). Available at: Accessed by: 08.30.2014. Russian (Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации (V пересмотр). Доступно на: Проверено 30.08.2014).

34. Johnson C., Waters D.D., DeMicco D.A. et al. Comparison of effectiveness of atorvastatin 10 mg versus 80 mg in reducing major cardiovascular events and repeat revascularization in patients with previous percutaneous coronary intervention (post hoc analysis of the Treating to New Targets [TNT] Study). Am J Cardiol 2008;102:1312-7.

35. Cannon C.P., Braunwald E., McCabe C.H. et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504.

36. Gibson C.M., Pride Y.B., Hochberg C.P. et al. Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy –Thrombolysis In Myocardial Infarction 22) Substudy. J Am Coll Cardiol 2009; 54(24):2290-5.

37. Patti G, Chello M, Candura D, et al. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 study. Circulation 2006; 114:1455-61.

38. Maisel W.H., Rawn J., Stevenson W.G. Atrial fibrillation after cardiac surgery. Ann Intern Med 2001;135:1061-73.

39. Hogue C.W. Jr, Creswell L.L., Gutterman D.D, Fleisher LA; American College of Chest Physicians. Epidemiology, mechanisms, and risks: American College of Chest Physicians guidelines for the prevention and management of postoperative atrial fibrillation after cardiac surgery. Chest 2005;128:9-16.

40. Mariscalco G., Klersy C., Zanobini M. et al. Atrial fibrillation after isolated coronary surgery affects late survival. Circulation 2008;118:1612-8.

41. Patti G., Tomai F., Melfi R. et al. Strategies of clopidogrel load and atorvastatin reload to prevent ischemic cerebral events in patients undergoing protected carotid stenting: Results of the randomized ARMYDA-9 CAROTID study. J Am Coll Cardiol 2013;61(13):1379-87.

42. Aspelin P., Aubry P., Fransson S.G. et al. for the NEPHRIC Study Investigators. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med 2003;348:491-499.

43. Rihal C.S., Textor S.C., Grill D.E. et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002;105:2259-2264.

44. McCullough P.A. Contrast-induced acute kidney injury. J Am Coll Cardiol 2008;51:1419-28.

45. Patti G., Ricottini E., Nusca A. et al. Short-term, high-dose Atorvastatin pretreatment to prevent contrastinduced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty-contrast-induced nephropathy] trial. Am J Cardiol 2011;108:1-7.

46. Gogolashvili NG. Atorvastatin or rosuvastatin? Choice from the perspective of evidence-based medicine. Cardiology 2012; 51 (7): 84-92. Russian (Гоголашвили Н.Г. Аторвастатин или розувастатин? Выбор с позиции доказательной медицины. Кардиология 2012;51(7):84-92).

47. Gilyarevsky SR. What is the selection of an optimal regimen of intensive statin therapy with evidencebased medicine? Russian Journal of Medicine 2013; 21 (4): 220-24. Russian (Гиляревский С.Р. Что такое выбор оптимального режима интенсивной терапии статином с позиции доказательной медицины? Русский Медицинский Журнал 2013; 21(4):220-24).


For citations:

Gogolashvili N.G. STATINS AND PERCUTANEOUS CORONARY INTERVENTION. FOCUS ON THE ATORVASTATIN. Rational Pharmacotherapy in Cardiology. 2014;10(4):438-443. (In Russ.)

Views: 598

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)